https://supportscience.uz/index.php/ojmp <p><a href="http://sjifactor.com/passport.php?id=22039"><strong>SJIF 2021-5.897, 2022-6.091</strong></a></p> <p><strong>“Oriental Journal of Medicine and Pharmacology</strong>” is a journal specializing in medical and pharmacological sciences, providing comprehensive coverage of scientific and practical innovations in the fields of physiology, anatomy, histology, cytology, biochemistry, pathological anatomy, physiological anatomy, general and clinical pharmacology, microbiology, widely and effectively use the possibilities of the journal. One of the most important tasks in the field of medicine is the publication of relevant, new, scientifically effective and verified information<strong>.</strong></p> <p>This scientific journal is published in the electronic version, comes out 6 times a year in Uzbek, English and Russian.</p> <p>The journal publishes the best scientific and journalistic works of Uzbek authors, as well as representatives of the world economy and agriculture.</p> en-US editor@supportscience.uz (Supportscience LLC) tech@supportscience.uz (Supportscience LLC) Thu, 09 Apr 2026 10:37:57 +0000 OJS 3.3.0.4 http://blogs.law.harvard.edu/tech/rss 60 https://supportscience.uz/index.php/ojmp/article/view/3886 <p>Over the past four decades, statins have remained the cornerstone of cardiovascular disease prevention, evolving from natural compounds to highly effective third-generation drugs. However, the persistence of residual cardiovascular risk, statin intolerance, and the need for deeper lipid reduction have led to the emergence of fourth-generation agents. This paper examines the modern pharmacological landscape, including both improved statins and new classes of lipid-lowering drugs with different mechanisms of action.</p> <p>Pitavastatin occupies an intermediate position, characterized by a favorable pharmacokinetic profile, minimal drug interactions, and a neutral effect on carbohydrate metabolism. Bempedoic acid represents an innovative drug that inhibits ATP citrate lyase, providing effective LDL cholesterol reduction without myotoxicity and demonstrating a reduction in cardiovascular events in patients with statin intolerance.</p> <p>PCSK9 inhibitors, including monoclonal antibodies (evolocumab, alirocumab) and RNA interference agents (inclisiran), provide significant reductions in LDL cholesterol levels and the incidence of major cardiovascular complications. Inclisiran is particularly notable for its convenience of use due to its twice-yearly administration.</p> <p>Promising agents such as obicetrapib and RNA-based therapies targeting lipoprotein(a) open new possibilities for reducing residual risk not directly related to LDL cholesterol levels. These advances reflect a shift from traditional statin monotherapy to a personalized approach in lipid metabolism management, taking into account individual risk, genetic factors, and therapy tolerability.</p> <p>Fourth-generation agents not only enhance the effectiveness of lipid-lowering therapy but also form a new paradigm for long-term cardiovascular disease prevention based on a comprehensive and individualized approach.</p> Farida Azizova, Shoymardon Turaev Copyright (c) 2026 Farida Azizova, Shoymardon Turaev https://creativecommons.org/licenses/by/4.0 https://supportscience.uz/index.php/ojmp/article/view/3886 Tue, 07 Apr 2026 00:00:00 +0000